Cosmos Health (NASDAQ:COSM) CEO Grigorios Siokas Buys 388,532 Shares of Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas bought 388,532 shares of the firm’s stock in a transaction on Thursday, February 12th. The stock was acquired at an average price of $0.37 per share, for a total transaction of $143,756.84. Following the completion of the purchase, the chief executive officer directly owned 8,861,914 shares in the company, valued at approximately $3,278,908.18. The trade was a 4.59% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Grigorios Siokas also recently made the following trade(s):

• On Wednesday, February 11th, Grigorios Siokas acquired 291,262 shares of Cosmos Health stock. The stock was purchased at an average price of $0.41 per share, with a total value of $119,417.42.
• On Friday, January 23rd, Grigorios Siokas purchased 90,325 shares of Cosmos Health stock. The shares were acquired at an average price of $0.50 per share, for a total transaction of $45,162.50.
• On Tuesday, January 20th, Grigorios Siokas purchased 353,321 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.50 per share, for a total transaction of $176,660.50.
• On Wednesday, January 14th, Grigorios Siokas purchased 493,495 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.45 per share, with a total value of $222,072.75.
• On Monday, January 12th, Grigorios Siokas bought 113,185 shares of Cosmos Health stock. The stock was bought at an average cost of $0.50 per share, with a total value of $56,592.50.
• On Thursday, January 8th, Grigorios Siokas bought 156,190 shares of Cosmos Health stock. The shares were bought at an average price of $0.52 per share, with a total value of $81,218.80.
• On Wednesday, January 7th, Grigorios Siokas purchased 124,880 shares of Cosmos Health stock. The shares were bought at an average price of $0.52 per share, for a total transaction of $64,937.60.
• On Tuesday, January 6th, Grigorios Siokas purchased 133,953 shares of Cosmos Health stock. The stock was bought at an average cost of $0.54 per share, for a total transaction of $72,334.62.
• On Friday, December 19th, Grigorios Siokas purchased 88,314 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.49 per share, with a total value of $43,273.86.
• On Monday, December 15th, Grigorios Siokas purchased 168,472 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.42 per share, with a total value of $70,758.24.

Cosmos Health Price Performance

COSM stock opened at $0.38 on Friday. Cosmos Health Inc. has a 1 year low of $0.28 and a 1 year high of $1.32. The company has a market cap of $14.35 million, a P/E ratio of -0.51 and a beta of 5.36. The firm has a 50-day moving average of $0.48 and a 200 day moving average of $0.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.99 and a quick ratio of 0.84.

Cosmos Health (NASDAQ:COSM) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.16). Cosmos Health had a negative net margin of 31.01% and a negative return on equity of 33.19%. The firm had revenue of $17.11 million for the quarter, compared to the consensus estimate of $16.40 million. On average, sell-side analysts forecast that Cosmos Health Inc. will post -0.78 EPS for the current year.

Hedge Funds Weigh In On Cosmos Health

A hedge fund recently raised its stake in Cosmos Health stock. Renaissance Technologies LLC increased its stake in Cosmos Health Inc. (NASDAQ:COSM) by 260.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 334,575 shares of the company’s stock after buying an additional 241,775 shares during the period. Renaissance Technologies LLC owned 0.89% of Cosmos Health worth $167,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 12.61% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cosmos Health in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cosmos Health presently has a consensus rating of “Sell”.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.